OncoSil shareholders back capital and remuneration resolutions at EGM

OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.

OncoSil Medical Ltd, an interventional oncology specialist focused on device-based treatments for advanced pancreatic cancer, has developed its OncoSil device to deliver targeted radiotherapy via Phosphorous-32 microparticles, and holds marketing approvals across over 30 countries including key European markets. The technology aims to improve outcomes in a cancer type with typically late diagnosis and poor long-term survival prospects.

The company reported that all resolutions put to shareholders at its 12 March 2026 extraordinary general meeting were passed by poll with strong voting support, including approvals related to placement shares, options, director participation in placements and remuneration shares for the CEO. The results clear the way for OncoSil to proceed with its capital-raising and incentive structures, supporting ongoing commercial rollout and corporate initiatives in its target oncology markets.

The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is an Australian-based global medical device company focused on interventional oncology, specialising in localised treatments for unresectable locally advanced pancreatic cancer. Its core product, the OncoSil device, uses targeted intratumoural placement of Phosphorous-32 microparticles alongside chemotherapy to deliver higher radiation doses directly to tumours while sparing surrounding organs, and is approved in more than 30 countries including in the EU and UK.

Average Trading Volume: 60,466

Technical Sentiment Signal: Sell

Current Market Cap: A$14.05M

For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.